Management to present at Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2016 financial results and provide 2017 guidance on Monday, February 13, 2017, and Invitae’s management team will host a conference call that day at 4:45 p.m. Eastern / 1:45 p.m. Pacific.
During the call, Invitae’s management team will briefly review financial results, guidance, and recent developments and will spend the majority of the call fielding questions from analysts and investors. Management also invites investors to submit questions to firstname.lastname@example.org at any time leading up to or during the call. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 60742797.
Additionally, Invitae announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 1:00 p.m. Eastern / 10:00 a.m. Pacific.
The live, listen-only webcasts of both the conference call and the presentation at Leerink may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusions of the call and presentation and will be archived on the company’s website.
Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. Additionally, the company has created a Genome Network to connect patients, clinicians, advocacy organizations, researchers, and drug developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. For more information, visit our website at invitae.com.
Source: Invitae Corporation